Circulating tumor DNA as a marker of residual tumor in colon cancer
نویسندگان
چکیده
منابع مشابه
Evaluating the Expression of Oct4 as a Prognostic Tumor Marker in Bladder Cancer
Objective(s)The key transcriptional regulator Oct4 is one of the self-renewal and differentiation-related factors in cancer stem cells, where it maintains "stemness" state. Cancer stem cells have been identified in a variety of solid malignancies. They are a small population of tumor cells with stem cell characteristics, which are a likely cause of relapse in cancer patients. Due to high incide...
متن کاملCirculating Tumor Cells as a Prognostic Marker in Pancreatic Cancer
Pancreatic cancer, with a patient survival rate among the worst of any solid cancer, is the fourth leading cause of cancer-related morbidity and mortality in Western countries (Tjensvoll et al., 2013). It leads to an estimated 227, 000 deaths per year worldwide and the 5 year survival rate is only 4.6% due to its early metastasis (Zhou et al., 2011). Most of the pancreatic cancer patients are a...
متن کاملCirculating nucleic acids as a tumor marker.
Patients suffering from malignant diseases have been shown to have increased amounts of cell free nucleic acids in their circulation. As genetic and epigenetic alterations are increasingly characterized in different types of tumors, such changes can be used to detect tumor-derived nucleic acids in the circulation. To date, nearly all tumor-associated nucleic acids have been detected in the plas...
متن کاملCell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
PURPOSE Circulating cell-free DNA in the blood of cancer patients harbors tumor-specific aberrations. Here, we investigated whether this DNA might also reflect the presence of circulating tumor cells (CTC). EXPERIMENTAL DESIGN To identify the source of cell-free DNA in blood, plasma derived from 81 patients with prostate cancer was examined for CTCs and cell-free DNA. An epithelial immunospot...
متن کاملCirculating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
BACKGROUND Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy. PATIENTS AND METHODS This prospective study involved 53 mCRC patients receiving standard first-line chemotherapy. Both ctDNA and CEA were assessed in plas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Colorectal Oncology
سال: 2018
ISSN: 2413-0583,2220-3478
DOI: 10.17650/2220-3478-2018-8-3-11-16